# NBTX earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/NBTX) · [Earnings tab](https://www.lopjlb.com/stock/NBTX?tab=earnings)

Updated: 2026-09-29T05:45:11

Quarters analyzed: 8

## Cross-quarter narrative

Across 8 calls for NBTX, management tone moved from +0.60 (2022 Q3) to +0.00 (2025 Q4). Latest guidance stance: vague. Latest desk line: n/a

## Latest CallCard · Q4

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2025 Q4:** —
- **2024 Q4:** Nanobiotix reported strong progress on its J&J collaboration, transferred the NANORAY-312 Phase 3 trial to Janssen, launched the Curadigm platform, and extended cash runway to mid‑2026 despite a one‑off negative revenue impact.
- **2024 Q1:** Nanobiotix updates NBTXR3 development: Janssen collaboration progressing with sponsorship transfer of NANORAY-312, protocol amendment removing futility analysis, interim analysis expected H1 2026, $20M milestone received, cash runway into Q3 2025, expanding to Curadigm and Oocuity platforms with H2 
- **2023 Q4:** Nanobiotix highlighted a $2.5 bn J&J licensing deal, positive Phase 1 data, progress on Phase 3 NANORAY‑312 and multiple early‑stage trials, while noting cash runway to Q3 2025 and pending data timelines.
- **2023 Q3:** Nanobiotix highlights $2.5B J&J collaboration, positive Phase 1 head/neck and pancreatic data, extended cash runway to mid-2025, and upcoming de-risk milestone.
- **2023 Q2:** Nanobiotix highlights transformative Janssen licensing deal for NBTXR3 with up to $1.8B milestones, extends cash runway to Q1 2024, and outlines multiple clinical catalysts including NANORAY-312 interim efficacy in H2 2024.
- **2022 Q4:** —
- **2022 Q3:** Nanobiotix reports Q3 2022 results; highlights Phase 1 study 1100 data in recurrent/metastatic head and neck cancer showing ORR 31% and disease control 71%; plans FDA protocol submission Q1 2023 for registration path; cash runway extended to Q1 2024 via EIB debt restructuring.

## Theme arcs

- **Management tone** (deteriorating): Δ mgmt=-0.60

## Fear persistence

- **clinical efficacy signal** [resolved]: 2022 Q3
- **regulatory design uncertainty** [resolved]: 2022 Q3
- **cash runway limitation** [resolved]: 2022 Q3
- **partnership dependency** [resolved]: 2022 Q3
- **clinical trial execution** [resolved]: 2022 Q3
- **accelerated approval pathway** [resolved]: 2022 Q3
- **competitive landscape** [resolved]: 2022 Q3
- **financing risk** [recurring]: 2022 Q3, 2023 Q3
- **clinical trial success** [resolved]: 2023 Q3
- **data comparability** [resolved]: 2023 Q3

## Guidance path

2022 Q3:vague → 2022 Q4:vague → 2023 Q2:vague → 2023 Q3:vague → 2023 Q4:vague → 2024 Q1:maintained → 2024 Q4:vague → 2025 Q4:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/NBTX`